A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
A Multicenter, Post-Market Follow-up Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
Visão geral do estudo
Status
Condições
Descrição detalhada
While studies support the clinical use of ChemoFx® in cancer patients, additional data are needed to further assess the utilization of this product in clinical practice. Such post-market data and information could be employed for product improvement as well as for the development of standards and regulations. This is a multicenter registry study of 3,000 patients with solid tumors. The study is not randomized, nor is it interventional in that the treating physician is free to choose how to employ ChemoFx® results in the clinical management of individual patients. Sites will be selected by Precision's clinical trials team based on past commercial usage of ChemoFx®.
Subjects who may be enrolled in this study are those who have been diagnosed with a solid tumor malignancy and for whom ChemoFx® has been ordered. ChemoFx® is ordered through the normal commercial process and is therefore billed to the patient's medical insurance.
All subjects will be appropriately consented before any study-specific data are collected. A limited dataset of patient demographics, oncology history, and therapeutic intervention will be collected in addition to ChemoFx® assay usage. Subjects will be treated based on the medical judgment of their treating physician(s). Patient survival data will be collected up to five years following the ChemoFx® commercial order. Additional disease progression data may be collected by Precision's CRAs at participating sites.
Optional Cell Research
Informed consent will be obtained to document subject's consent to use excess cells remaining in Precisions' commercial laboratory for additional research. This portion of the study may involve DNA, RNA, and proteomic research. To ensure the anonymity of each subject, any identifiers that would link the sample to the subject will be removed. The samples would then have gene expression profiling and or quantitative protein expression analysis performed. The goal of the research would be to identify a set of informative genes, intermediaries, and proteins and develop predictive algorithm(s) that seek to link the expression level of the gene, gene signature, intermediary, or protein to the clinical outcome of the patient. This portion of the study does not require any additional subject procedures. Neither physicians nor their patients will receive the results of the research performed. Results will not be placed in the subjects health care records and will not affect their medical care.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35213
- Cardio-Thoracic Surgeons, P.C.
-
-
California
-
Oakland, California, Estados Unidos, 94609
- Hematology Oncology Associates
-
-
Florida
-
Boynton Beach, Florida, Estados Unidos, 33435
- Collaborative Research Group
-
Fort Lauderdale, Florida, Estados Unidos, 33308
- Broward Oncology Associates, P.A.
-
Hollywood, Florida, Estados Unidos, 33021
- The Center For Gynecologic Oncology
-
Miami, Florida, Estados Unidos, 33143
- GYN Oncology of Miami
-
Miami, Florida, Estados Unidos, 33173
- Miami International Surgical Services
-
Orlando, Florida, Estados Unidos, 32804
- Orlando Cardiovascular Institute PA
-
-
Illinois
-
Skokie, Illinois, Estados Unidos, 60076
- Edward H. Kaplan, M.D. & Associates
-
-
Iowa
-
Des Moines, Iowa, Estados Unidos, 50309
- Iowa Clinic
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40503
- Central Baptist Hospital Clinical Research Center
-
Paducah, Kentucky, Estados Unidos, 42003
- Oncology Associates of West Kentucky
-
-
Michigan
-
Grand Blanc, Michigan, Estados Unidos, 48439
- Grand Blanc Surgical Specialist
-
-
New York
-
Albany, New York, Estados Unidos, 12208
- Albany Thoracic & Esophageal Surgery
-
East Setauket, New York, Estados Unidos, 11733
- North Shore Hematology Oncology
-
Flushing, New York, Estados Unidos, 11355
- The New York Hospital Medical Center of Queens
-
Mineola, New York, Estados Unidos, 11501
- Winthrop University Hospital
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Center for Clinical Research and Technology University Hospitals of Cleveland
-
-
Pennsylvania
-
Erie, Pennsylvania, Estados Unidos, 16505
- The Regional Cancer Center
-
-
Texas
-
Houston, Texas, Estados Unidos, 77090
- Northwest Cancer Center
-
Houston, Texas, Estados Unidos, 77054
- Colorectal Surgical Associates
-
Houston, Texas, Estados Unidos, 77024
- Barry S Siller MD
-
San Antonio, Texas, Estados Unidos, 78229
- Cancer Care Centers of South Texas
-
-
Washington
-
Spokane, Washington, Estados Unidos, 99202
- Cancer Care Northwest
-
-
West Virginia
-
Morgantown, West Virginia, Estados Unidos, 26508
- Heiskell, King, Burns & Tallman Surgical Associates, Inc.
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Pathologically confirmed diagnosis of solid tumor malignancy;
- Medically indicated to receive chemotherapy;
- Fresh tissue submitted from the solid tumor malignancy for testing with the ChemoFx® assay after August, 2006;
- Final ChemoFx® assay report is available;
- Subject must be at least 18 years of age;
- Subject must sign and date an IRB approved ICF.
Exclusion Criteria:
- Enrolled in PT-103, PT-106, PT-206, PT-301, or PT-304;
- Pregnant or lactating subjects;
- Subjects are not indicated to receive chemotherapy for their disease;
- Subjects with psychiatric or addictive disorders that would preclude obtaining informed consent.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
To determine physicians' rate of compliance with ChemoFx assay results in the treatment of subjects with solid tumors.
Prazo: Analysis of assay-directed compliance will be conducted immediately after information is collected.
|
Analysis of assay-directed compliance will be conducted immediately after information is collected.
|
|
To investigate the association between the results of Precision's ChemoFx assay results and overall survival in subjects with solid tumors.
Prazo: From date of first dose of on-study chemotherapy to date of death or last known alive.
|
From date of first dose of on-study chemotherapy to date of death or last known alive.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Karl Williams, M.D., Precision Therapeutics, Inc.
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- PT-207
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .